Dataset Information

Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer

ABSTRACT: While pancreatic ductal adenocarcinomas (PDAC) are addicted to KRAS-activating mutations, inhibitors of downstream effectors in the KRAS pathway, such as the clinically approved MEK1/2 kinases inhibitor Trametinib, are devoid of significant therapeutic effects. Nevertheless, the extensive rewiring of regulatory circuits driven by the attenuation of the KRAS pathway can induce novel functional states and vulnerabilities of potential therapeutic relevance. Here, we performed a quantitative histone post-translatinal modification analysis of PDAC cells in the initial hours after MEK1/2 inhibition by Trametinib.

INSTRUMENT(S): Q Exactive Plus

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Pancreatic Cancer

SUBMITTER: Roberta Noberini

LAB HEAD: Tiziana Bonaldi

PROVIDER: PXD043559 | Pride | 2024-06-16

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 18

Publications

Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer.

Cortesi Alice A Gandolfi Francesco F Arco Fabiana F Di Chiaro Pierluigi P Valli Emanuele E Polletti Sara S Noberini Roberta R Gualdrini Francesco F Attanasio Sergio S Citron Francesca F Ho I-Lin IL Shah Rutvi R Yen Er-Yen EY Spinella Mara Cetty MC Ronzoni Simona S Rodighiero Simona S Mitro Nico N Bonaldi Tiziana T Ghisletti Serena S Monticelli Silvia S Viale Andrea A Diaferia Giuseppe Riccardo GR Natoli Gioacchino G

Science advances 20240327 13

While pancreatic ductal adenocarcinomas (PDACs) are addicted to KRAS-activating mutations, inhibitors of downstream KRAS effectors, such as the MEK1/2 kinase inhibitor trametinib, are devoid of therapeutic effects. However, the extensive rewiring of regulatory circuits driven by the attenuation of the KRAS pathway may induce vulnerabilities of therapeutic relevance. An in-depth molecular analysis of the transcriptional and epigenomic alterations occurring in PDAC cells in the initial hours after ...[more]

PMID: 38536927

			Action	DRS
	Cortesi.zip	Other
	Experimental_design.txt	Txt
	QEP220510_RN_1.raw	Raw
	QEP220510_RN_10.raw	Raw
	QEP220510_RN_11.raw	Raw

Dataset Information

Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer

Dataset's files

Publications

Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer [RNA-seq]
2024-02-19 | GSE238198 | GEO

Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer [ChIP-seq]
2024-02-19 | GSE238197 | GEO

Acute and chronic treatment of trametinib plus lapatinib in patient-derived xenografts (PDX) of pancreatic adenocarcinoma (PDAC)
2017-05-02 | GSE98399 | GEO

Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function
2023-09-25 | GSE239737 | GEO

RNA-seq of pancreatic mouse tumor cell lines
2021-11-29 | E-MTAB-11187 | biostudies-arrayexpress

Single cell RNA-seq of pancreatic mouse tumors upon treatment
2021-11-13 | E-MTAB-9954 | biostudies-arrayexpress

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation
2024-05-17 | GSE236258 | GEO

Combinatorial high throughput drug screening identifies a synergistic drug interaction that sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade
2022-02-11 | PXD027877 | Pride

Combinatorial high throughput drug screening identifies a synergistic drug interaction that sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade
2022-02-23 | PXD023267 | Pride

Histone PTMs profiles of maltonis treated cells
2023-02-13 | PXD031448 | Pride